深圳市临床急需进口港澳药品配送服务 磷酸芦可替尼乳膏 薄膜包衣片 尘螨变应原舌下片 氟替美维吸入粉雾剂 预充笔肾上腺素注射液招标公告（深圳市前海蛇口自贸区医院(深圳市南山区蛇口人民医院)2025）
“华润广东医药有限公司”及“国药控股广州有限公司”为进口港澳药品配送服务配送商，我院拟于近期以单一来源谈判方式开展采购。
如有异议，请在公示期内向深圳市前海蛇口自贸区医院招标采购办公室反映，公示期为三天，逾期将不再受理。
深圳市前海蛇口自贸区医院
招标采购办公室
2025年04月09日
获批港澳药品情况：
202504091004213280.xlsx
厂家产品授权书：
202504091004517527.rar
\n深圳市前海蛇口自贸区医院获批港澳药品情况\n\n序号\n药品\n厂家授权供应商\n\n1\n阿扎胞苷片\n华润广东医药有限公司\n\n3\n布西珠单抗\n华润广东医药有限公司\n\n5\n曲美木单抗\n华润广东医药有限公司\n\n7\n巴氯芬注射液\n华润广东医药有限公司\n\n8\n阿伏利尤单抗\n华润广东医药有限公司\n\n9\n磷酸芦可替尼乳膏\n华润广东医药有限公司\n\n10\n瑞玛奈珠单抗\n华润广东医药有限公司\n\n11\n伊曲莫德片\n华润广东医药有限公司\n\n12\n罗莫佐单抗\n华润广东医药有限公司\n\n13\n特泽利尤单抗\n华润广东医药有限公司\n\n14\n艾拉司群片\n华润广东医药有限公司\n\n15\n阿培利司薄膜包衣片\n华润广东医药有限公司\n\n16\n尘螨变应原舌下片\n华润广东医药有限公司\n\n18\n氟替美维吸入粉雾剂\n华润广东医药有限公司\n\n19\n预充笔肾上腺素注射液\n国药控股广州有限公司\n\n\nEVERESTMEDICINESTOWHOMITMAYCONCERN:敬启者RE:LETTEROFAUTHORIZATION关于：授权信DearSir/MadamWe,EverestMedicines(Singapore）Pte.Ltd，istheMarketAuthorizationHolderofVelsipity（“productintheterritoryofMacaoSAR本公司EverestMedicines（Singapore)Pte.Ltd.，是Velsipity（“产品”）在澳门特别行政区的上市许可持有人。We,EverestMedicinesSingapore）Pte.Ltd，herebyauthorizesthedesignateddistributorChinaResourcesGuangdongPharmaceuticalCo，Ltd.tosupplytheMacao-registeredproductttotheninecitiesintheChineseMainlandoftheGuangdong-HongKong-MacaoGreaterBayAreaofthePeople'sRepublicofChinaunderapplicableregulations本公司EverestMedicines(Singapore）Pte.Ltd.特此授权指定经销商（华润广东医药有限公司）根据适用的法规于中华人民共和国粤港澳大湾区内地九市供应已于澳门登记的产品。Thisauthorizationshallbeeffectiveon26/08/2024（DMY）untilfurthernotice本授权书于2024年8月26日生效，直至另行通知。Yoursfaithfully此致Everest1EverestMedicinesSingaporepte.Ltda0POSITION:CEODATE:26/08/2024ALK-Abell6A/STOWHOMITMAYCONCERN:敬启者RE:LETTEROFAUTHORIZATION关于：授权信DearSir/MadamWe,ALK-Abell6A/S,istheMarketAuthorizationHolderofACARIZAX®12SQ-HDMinMacaoSpecialdministrationRegion本公司ALK-AbelloA/S，是ACARIZAX®12SQ-HDM在澳门特别行政区的上市许可持有人。We,ALK-Abell6A/S,herebyauthorizesthedesignateddistributorChinaResourcesGuangdongPharmaceuticalCo.，LtdtosupplytheMacao-registeredproductACARIZAX®12SQ-HDMinthenineChineseMainlandcitiesoftheGuangdong-HongKong-MacaoGreaterBayAreaofthePeoplesRepublicofChinaunderapplicableregulations本公司ALK-AbellA/S特此授权指定经销商（华润广东医药有限公司）根据适用的法规于中华人民共和国粤港澳大湾区内地九市供应已于澳门登记的产品ACARIZAX®12SQ-HDM。Thisauthorizationshallbeeffectiveon2024/11/20untilfurthernotice本授权书于2024/11/20生效，直至另行通知。Yoursfaithfully此致ALK-AbelloA/SSIGNATURE（COMPANYSEAL）SgeEnO.h2ECECNAMEEVpPOSITION10DATE2025.AstraZenecaTOWHOMITMAYCONCERN:AstraZenecaABSE-15185Sodertalje,Sweden敬启者T:+46855326000F:+46855329000RE:LETTEROFAUTHORIZATIONastrazeneca.com关于：授权信DearSir/MadamWe,AstraZenecaAB,herebyconfirmthatFourStarCompanyLimitedisourexclusivedistributorintheterritoryofMacaoSpecialAdministrativeRegionofthePeoplesRepublicofChina(MSAR.本公司AstraZenecaAB现确认科达有限公司是本公司于澳门特别行政区的分销商。We,AstraZenecaAB,herebyauthorizeFourStarCompanyLimitedtoexpanditsterritoryintotheGreaterBayArea(GBA)ofthePeoplesRepublicofChinaforthesupplyofMacao-enlisteddrugsthroughthedesignateddistributor（ChinaResourcesGuangdongPharmaceuticalCo.,Ltd.）totheGreaterBayAreaofthePeoplesRepublicofChinaundertheapplicablepolicies（productnameIMJUDO300mg/15mL）.本公司AstraZenecaAB特此授权科达有限公司扩大其分销地区至中华人民共和国粤港澳大湾区，并通过指定经销商（华润广东医药有限公司）根据适用的法规于中华人民共和国粤港澳大湾区供应已于澳门登记的药品（产品名称IMJUDO300mg/15mL）。ThisauthorizationshallbeeffectiveonNovember22,2023untilfurthernotice本授权书于2023年11月22日生效，直至另行通知。Yoursfaithfully此致，SignedforandonbehalfofAstraZenecaAB（publ)December12.2023MariaPeterssonDateRegulatoryAffairsGroupDirector23128008aABRegOfficeAstraZenecaAB（publSE-15185Sodertalje,SwedenRegNo556011-7482AstraZenecaAstraZenecaHongKongLimited阿斯利康香港有限公司Date:1March2024TOWHOMITMAYCONCERN敬后者RE:LETTEROFAUTHORIZATION矣于：授权信DearSir/MadamWe,AstraZenecaHongKongLimited,herebyconfirmthatZuelligPharmaLimited(ZP）isourexclusivedistributorintheterritoryoftheHongKongSpecialAdministrativeRegionofthePeople'sRepublicofChinaHKSAR)本公司阿斯利康香港有限公司现确认裕利医药有限公司是本公司于香港特别行政区的分销商·We,AstraZenecaHongKongLimitedherebyauthorizeZuelligPharmaLimited（ZP）toexpanditsterritoryintotheGreaterBayArea(GBA）ofthePeoplesRepublicofChinaforthesupplyofHK-registereddrugsthroughthedesignateddistributor(ChinaResourcesGuangdongPharmaceuticalCo.,Ltd).totheGreaterBayAreaofthePeople'sRepublicofChinaundertheapplicablepolicies:Productname:Saphnelo本公司阿斯利康香港有限公司特此授权裕利医药有限公司扩大其分销地区至中华人民共和国粤港澳大湾区，并通过指定经销商（华润广东医药有限公司）根据适用的法规于中华人民共和国粤港澳大湾区供应已于香港注册的药品：产品名称：SaphneloThisauthorizationshallbeeffectiveonMarch1,2024untilfurthernotice本授权书于2024年3月1日生效，直至另行通知。Yoursfaithfully此致，ShanWu吴珊GeneralManagerofAstraZenecaHongKong&Macau阿斯利康中国香港及澳门总经理AstraZenecaHongKongLimited阿斯利康香港有限公司AstraZenecaHongKongLimitedTel:（852）24207388Unit1-3,11/FFax:（852）2422678818KingWahRoadWebsite:www.astrazeneca.comNorthPointMailingAddress:P.O.BoxNo.11009GeneralPostOffice,Central.HongKongHongKongAMGENAmgenHongKongLimitedneislandFst18Westand.RuadHongKonDate:21May2024TOWHOMITMAYCONCERN:敬启者RE:LETTEROFAUTHORIZATION矣于：授权信DearSir/MadamWe,AMGENHONGKONGLIMITED,herebyconfirmthatZuelligPharmaLimitedisourexclusivedistributorintheterritoryofHongKongSAR本公司AMGENHONGKONGLIMITED·现确认裕利医药有限公司是本公司于香港特别行政区的分销商·We,AMGENHONGKONGLIMITED,herebyauthorizeZuelligPharmaLimitedtoexpanditsterritoryintotheGreaterBayArea(GBA）ofthePeoplesRepublicofChinaforthesupplyofHongKong-registereddrugsthroughthedesignateddistributorChinaResourcesGuangdongPharmaceuticalCo.,Ltd.totheGreaterBayAreaofthePeoplesRepublicofChinaundertheapplicablepolicies(productnameEVENITY).本公司AMGENHONGKONGLIMITED·特此授权裕利医药有限公司扩大其分销地区至中华人民共和国粤港澳大湾区·并通过指定经销商（华润广东医药有限公司）根据适用的法规于中华人民共和国粤港澳大湾区供应已于香港注册的药品（产品名称EVENITY）Thisauthorizationshallbeeffectiveon2024/05/21untilfurthernotice本授权书于2024/05/21生效·直至另行通知。AMGENAmgenHongKongLimited（ng18Westand.RoadHonKunYoursfaithfully此致安進香港有限公KaraCheungGeneralManager-HongKong&MacauAmgenHongKongLimitedSuites407-412,4/F,OnelslandEast18WestlandsRoadQuarryBay,HongKongTel:（852）2843-1188Mobile:（852）6718-1787Email:kcheun01@amgen.comDocusignEnvelopeID:BOAAE6E4-16F7-4DFC-AD6C-12AB5A43CC23StemlineStemlineTherapeutics,Inc.750LexingtonAvenueFourthFloorNewYork.NY10022www.menarinistemline.com授权委托书LetterofAuthorizationStemlineTherapeuticsInc.（Stemline）注册地址为750LexingtonAvenue,4thfloor,NewYorkNY10022,UnitedStatesofAmerica，是ORSERDUT(elacestrant）86毫克及345毫克片剂在中华人民共和国澳门特别行政区的上市许可持有人（MAH）。StemlineTherapeuticsInc(Stemline)，havingitsregisteredofficeat750LexingtonAvenue，4floor,NewYork，NY10022,UnitedStatesofAmerica，istheMarketingAuthorizationHolderMAH）forORSERDUTM(elacestrant)tablets86mgand345mginMacaoSpecialAdministrativeRegionofthePeople'sRepublicofChina.我方，即下方签名公司StemlineTherapeutics,Inc.，特此授权SciClonePharmaceuticalsLimited（“SciClone)，注册地为香港新界荃湾白田坝街23-39号长丰工业大厦第三单元14楼3室，接收由我方供应的ORSERDUM(elacestrant）86毫克及345毫克片剂，存储于SciClone在香港委托的物流服务商Pharmtech（HongKong）Limited位于6/F&UNITSIB,1C,2B-1,5/F,2STORERMSOFUNIT10,18/F,23-39PAKTINPARST,TSUENWANNT的仓库，并根据粤港澳大湾区内地九市临床急需进口港澳药械政策，仅转出口至中华人民共和国粤港澳大湾区广东省九市（如下定义）。We，theundersignedcompany，StemlineTherapeutics，Inc，hereby，authorize,SciClonePharmaceuticalsLimited（SciCloneregisteredatUnit314/FCheungFungIndustrialBuilding,23-39PakTinParStreet,TsuenWan,NewTerritories,HongKong，tobesuppliedwiththeORSERDUTM(elacestrant)tablets86mgand345mgbyStemline,tostorethesameproductinthewarehouseofPharmtechHongKong）Limited,alogisticsserviceproviderentrustedbySciCloneinHongKong,locatedat6/F&UNITS1B,1C,2B-1,5/F,2STORERMSOFUNIT10,18/F,23-39PAKTINPARST,TSUENWAN,NT,andtoreexportthesameproductsolelyintothePilotZones（ashereinafterdefined)ofPeople'sRepublicofChinaunderthepolicyforimportingHongKongandMacaodrugsandmedicaldevicesurgentlyneededforclinicaluseinninecitiesintheGuangdong-HongKong-MacaoGreaterBayAreaDocusignEnvelopeID:BOAAE6E4-16F7-4DFC-AD6C-12AB5A43CC23StemlineStemlineTherapeutics,Inc750LexingtonAvenueFourthFloorNewYork,NY10022www.menarinistemline.comSciClonePharmaceuticalsLimited将通过指定经销商（华润广东医药有限公司）根据适用的法律、法规及政策于中华人民共和国粤港澳大湾区广东省九市（广州、深圳、珠海、佛山、惠州、东莞、中山、江门、肇庆）（统称为‘中华人民共和国粤港澳大湾区广东省九市’）供应ORSERDUTM（elacestrant)。ORSERDUT(elacestrant）已于香港和澳门注册登记。SciClonePharmaceuticalsLimitedwilldeliverORSERDUT（elacestrant）throughthedesignateddistributor（ChinaResourcesGuangdongPharmaceuticalCo.,Ltd.）totheninemunicipalities（Guangzhou，Shenzhen，Zhuhai，Foshan，Huizhou，Dongguan，Zhongshan，JiangmenandZhaoqing）inGuangdongProvinceintheGuangdong-HongKong-MacaoGreaterBayArea（GBA）ofthePeople'sRepublicofChina（collectively，thePilotZones）underallapplicablelaws,regulationsandpolicies.ORSERDU™(elacestrant）isregisteredinHongKongandMacao.我方，即下方签名公司StemlineTherapeutics，Inc.，特此保证供应大湾区的ORSERDUTM(elacestrant）产品的质量与港澳上市的ORSERDU™(elacestrant）产品质量一致。We,theundersignedcompany,StemlineTherapeutics,Inc.,herebyguaranteethatthequalityofORSERDUM（elacestrant）suppliedtotheGreaterBayAreaisconsistentwiththequalityofORSERDUM(elacestrant)listedinHongKongorMacao.本授权应持续有效，直至NMPA授予ORSERDUT(elacestrant）监管批准。ThisauthorizationshallremainvalidandeffectiveuntilthegrantingoftheRegulatoryApprovalbytheNMPAforORSERDU(elacestrant）.本授权自尾页注明的日期生效，Stemline或SciClone有权在提前至少（60）个日历日发出书面通知后，有因或无因终止本授权，且不对另一方主张违约责任。ThisLetterofAuthorizationshalltakeeffectasofthedateindicatedonthelastpage，eitherStemlineorSciClonemayterminatethisauthorizationwithpriorwrittennotice,atleast（60)calendardaysinadvance,andforanyornoreason,andwithoutpenaltytowardstheotherpartyDocusignEnvelopeID:BOAAE6E4-16F7-4DFC-AD6C-12AB5A43CC23StemlineStemlineTherapeutics,Inc.750LexingtonAvenueFourthFloorNewYork.NY10022www.menarinistemline.com谨代表StemlineTherapeutics,Inc.ForandonbehalfofStemlineTherapeutics,Inc—Signedby:Doilaom姓名Name:DavidGIONCO-81379B6BA8BD435.日期Date:February11，2025一6:23PMES粤澳港大湾区药品销售合同本药品销售合同（“本合同”）由以下双方签订：甲方：美倫有限公司，一家根据香港法律依法成立并存续的有限责任公司，其地址为香港九龍紅砌鶴翔街8號維港中心第2座905室乙方：华润广东医药有限公司，一家根据中华人民共和国法律依法成立并存续的有限责任公司，其地址为中国广东省广州市越秀区沿江中路298号中区五楼、十楼。鉴于：1.依据2020年9月29日《市场监管总局等部门关于印发管创新发展工作方案>的通知》（国市监药（2020）159号，以下简称“大湾区工作方案”）、《广东省粤港澳大湾区内地临床急需进口港澳药品医疗器械管理暂行规定》等文件对粤港澳大湾区的医疗一体化建设提出了总体要求、重点任务和保障措施的工作要求，以深入实施《粤港澳大湾区发展规划纲要》，促进医药产业在粤港澳大湾区融合发展，更好地满足粤港澳大湾区居民用药用械需求，保障用药用械安全，塑造具有创新活力的健康湾区；2.甲方是附件药品在中国香港地区的药品经销商。甲方希望积极响应大湾区工作方案，参与推进粤港澳大湾区医疗一体化建设；3.乙方拥有在中国市场经营及分销药品的合法资质。在大湾区工作方案的文件指引下，乙方希望根据方案中提出的指导原则以及程序，向甲方采购药品，用于满足大湾区工作方案中述及的符合要求的指定医疗机构的药品采购需求；4.乙方业已获得符合要求的指定医疗机构委托乙方采购、进口和配送本协议项下药品的正式授权。5.符合要求的指定医疗机构名单可参考附件三兹此，甲乙双方在平等互利的基础上达成如下一致协议：第1条定义除本合同文义另有所指，下列词语应具有如下含义“药品”指甲方销售给乙方的产品（产品清单详见附件二）；“相关知识产权”指甲方和/或其关联企业对下述载体所享有的所有权或使用权：i)甲方和/或其关联企业的已注册的、正在申请注册的和尚未申请注册的商标（包括商品商标、服务商标和集体商标、证明商标）；ii）甲方和/或其关联企业的企业名称、商号、商誉；iii）1（本页为签署页）甲方：美价有限公司乙方：华润广东医药有限公司公司盖章：MEMForandonbehalfof公司盖章：IED代表签署代表签署：得数州Director(s）日期：日期：221.312024.2.2.11附件二产品清单甲、乙双方每半年更新本产品清单，更新形式为：双方在新的产品清单上加盖公章。品名规格MAH巴氯芬注射液（Sintetica）10mg/5ml；0.05mg/1mlMEKIMLTD甲方美价有限p乙方：华润广东医药有限公司公司盖章；公司盖章：城放能Oirector(s日期：0041.31日期：2742.214GLAXOSMITHKLINELIMITEDTOWHOMITMAYCONCERN:敬启者RE:LETTEROFAUTHORIZATION关于：授权信DearSir/MadamWe,GLAXOSMITHKLINELIMITED,istheMarketAuthorizationHolderoftheproductslistedbelowinHongKongSpecialAdministrationRegion本公司GLAXOSMITHKLINELIMITED，是下述产品在香港特别行政区的上市许可持有人。We，GLAXOSMITHKLINELIMITED，herebyauthorizesthedesignateddistributorChinaResourcesGuangdongPharmaceuticalCo.,Ltd.tosupplytheHongKong-registeredproductslistedbelowtotheninecitiesintheChineseMainlandoftheGuangdong-HongKong-MacaoGreaterBayAreaofthePeople'sRepublicofChinaunderapplicableregulations本公司GLAXOSMITHKLINELIMITED特此授权指定经销商（华润广东医药有限公司）根据适用的法规于中华人民共和国粤港澳大湾区内地九市供应下述已于香港注册的产品。Product/产品TrelegyEllipta,200mcg/62.5mcg/25mcgTrelegyEllipta,100mcg/62.5mcg/25mcgThisauthorizationshallbeeffectiveonuntil31Dec2026.il-FtB20251-F28-2025生效，直31Dec2026本授权书于Yoursfaithfully此致GLAXOSMITHKLINELIMITEDTHKLGSKSIGNATURE（COMPANYSEAL）TEOZEFCNG,NICHOLA5NAMEPOSITIONNGEERLMANAGCRDATEH-FCB-2025ALKMEMOTo:TOWHOMITMAYCONCERN17December2024LETTEROFAUTHORISATIONDearSir/MadamWe,ALK-Abell6AS,herebyauthoriseGrandPharmaceuticalGroupLimitedtoeX-panditsTerritoryintoGreaterBayArea(GBA)ofthePeoplesRepublicofChinaforthesupplyofHK-registeredJex®（Solutionforinjectioninpre-filledpenAdrenalineHongKongregistrationCertificatenumber:HK-64270)throughthedesignatedSi-nopharmHoldingGuangzhouCo.,Ltd.totheGreaterBayareaofthePeoplesRe-publicofChinaunderapplicablepoliciesPRODUCT1Jext®300mcgSolutionforinjectioninpre-filledpenAdrenalineHongKongregistrationcertificatenumber:HK-64270eutica/ALK遠大ALK-ARELL6ASYoursfaithfully醫藥集图BCGEALLE1PO.BOX408有限公司DK-2970HORSHOLMABELLODENMARKTEL+4545747576OS7GORFAX+4545748690OlestergaardAssociatedGlobalSupplyChainDirectorGlobalSupplyChainManagementALK-Abell6AS11BristolMyersSquibbTOWHOMITMAYCONCERN:敬启者RE:LETTEROFAUTHORIZATION关于：授权信DearSir/MadamWe,BRISTOL-MYERSSQUIBBPHARMA（HK）LTD,herebyconfirmthatDKSHHONGKONGLIMITEDisourexclusivedistributorintheterritoryofHongKongSARandMacaoSAR本公司BRISTOL-MYERSSQUIBBPHARMA（HK）LTD，现确认大昌华嘉香港有限公司是本公司于香港特别行政区及澳门特别行政区的分销商。We,BRISTOL-MYERSSQUIBBPHARMA（HK）LTD,herebyauthorizeDKSHHONGKONGLIMITEDtoexpanditsterritoryintotheGreaterBayArea（GBA)ofthePeople'sRepublicofChinaforthesupplyofHongKongregistereddrugsthroughthedesignateddistributorChinaResourcesGuangdongPharmaceuticalCo.,Ltd.totheGreaterBayAreaofthePeople'sRepublicofChinaundertheapplicablepoliciesproductname:Onureg）本公司BRISTOL-MYERSSQUIBBPHARMA（HK）LTD，特此授权大昌华嘉香港有限公司扩大其分销地区至中华人民共和国粤港澳大湾区，并通过指定经销商（华润广东医药有限公司）根据适用的法规于中华人民共和国粤港澳大湾区供应已于香港注册的药品（产品名称：Onureg）。Thisauthorizationshallbeeffectiveon07/02/2024untilfurthernotice.本授权书于07/02/2024生效，直至另行通知。Yoursfaithfully，此致MM大nVWVHNAME：ELBERTMANPOSITION:HeadofChinaInnovativeMedicinesBusinessUnitGeneralManagerofHongKongBRISTOL-MYERSSQUIBBPHARMA（HKLTDNAME：ELBERTMANPOSITION:HeadofChinaInnovativeMedicinesBusinessUnitGeneralManagerofHongKongBRISTOL-MYERSSQUIBBPHARMA（HKLTDDATE07/02/2024tevaTOWHOMITMAYCONCERN:敬启者RE:LETTEROFAUTHORIZATION关于：授权信DearSir/MadamWe,TevaPharmaceuticalHongKongO/BTevaPharmaceuticalHongKongLimited,herebyconfirmthatKerryPharma（HongKong)LimitedisourexclusivedistrbutorintheterritoryofHongKongSARandMacaoSAR本公司TevaPharmaceuticalHongKongO/BTevaPharmaceuticalHongKongLimited，现确认嘉里医药（香港）有限公司是本公司于香港特别行政区及澳门特别行政区的分销商。We,TevaPharmaceuticalHongKongO/BTevaPharmaceuticalHongKongLimitedherebyauthorizeKerryPharma（HongKong)LimitedtoexpanditsterritoryintotheGreaterBayArea(GBA）ofthePeoplesRepublicofChinaforthesupplyofHongKongregistereddrugsthroughthedesignateddistributorChinaResourcesGuangdongPharmaceuticalCo.,Ltd.totheGreaterBayAreaofthePeoplesRepublicofChinaundertheapplicablepolicies（productname:AJOVY)本公司TevaPharmaceuticalHongKongO/BTevaPharmaceuticalHongKongLimited，特此授权嘉里医药（香港）有限公司扩大其分销地区至中华人民共和国粤港澳大湾区，并通过指定经销商（华润广东医药有限公司）根据适用的法规于中华人民共和国粤港澳大湾区供应已于香港注册的药品（产品名称：AJOVY）。Thisauthorizationshallbeeffectiveon2024/07/01untilfurthernotice本授权书于2024/07/01生效，直至另行通知。Yoursfaithfully此致LindaPangHeadofCommercial,GreaterChina28June2024TevaPharmaceuticalHongKongLimitedUnit2303,23/F..MiraPlaceTowerA,132NathanRoadT:+85237019100F:+85226632662www.tevapharm.comTsimShaTsui,Kowloon,HongKongAstraZenecaAstraZenecaHongKongLimited阿斯利康香港有限公司Date:March4,2024TOWHOMITMAYCONCERN敬后者RE:LETTEROFAUTHORIZATION矣于：授权信DearSir/MadamWe,AstraZenecaHongKongLimited,herebyconfirmthatZuelligPharmaLimitedisourexclusivedistributorintheteritoryoftheHongKongSpecialAdministrativeRegionofthePeoplesRepublicofChina（HKSAR本公司阿斯利康香港有限公司现确认裕利医药有限公司是本公司于香港特别行政区的分销商·We,AstraZenecaHongKongLimited,herebyauthorizeZuelligPharmaLimitedtoexpanditsteritoryintotheGreaterBayArea(GBA）ofthePeople'sRepublicofChinaforthesupplyofHK-registereddrugsthroughthedesignateddistibutor（ChinaResourcesGuangdongPharmaceuticalCo.,Ltd).totheGreaterBayAreaofthePeople'sRepublicofChinaundertheapplicablepolicies:Productname:Tezspire本公司阿斯利康香港有限公司特此授权裕利医药有限公司扩大其分销地区至中华人民共和国粤港澳大湾区，并通过指定经销商（华润广东医药有限公司）根据适用的法规于中华人民共和国粤港澳大湾区供应已于香港注册的药品：产品名称：TezspireThisauthorizationshallbeeffectiveonMarch4,2024untilfurthernotice本授权书于2024年3月4日生效，直至另行通知。Yoursfaithfully此致，ShanWu吴珊GeneralManagerofAstraZenecaHongKong&Macau阿斯利康中国香港及澳门总经理AstraZenecaHongKongLimited阿斯利康香港有限公司AstraZenecaHongKongLimitedTel:（852）24207388Unit1-3,11/FFax:（852）2422678818KingWahRoadWebsite:www.astrazeneca.comNorthPointMailingAddress:P.O.BoxNo.11009GeneralPostOffice,Central.HongKongHongKongIncyteNlncgteBiosciencesDistributionB.VSOLVEPaasheuvetweg251105BPAmsterdamONNethertandwww.incute.comTOWHOMITMAYGONCERN:Efr.E&RE:LETTEROFAUTHORIZATION*f:ffifl'fHDearSir/MadamWe,lncyteBiosciencesDistributionB.V.,herebyconfirmthatWuzhouDruglnternationalTradingLimitedisoursub-distributorintheterritoryofMacaoSpecialAdministrativeRegionfortheproductnamedRUXOLITINIBCREAM15MG/G(the"Product").4a\-"llncyteBiosciencesDistributionB.V.IjilEfri^fr{'il24+n\FH.hHFV.l}a1EAa\f,FFn(PfaZffiRUXOLlTlNlBCREAM1sMG/G,XTffiffi"Pffi")+i4llt+fiUfr&Xtu1++Hffi"We,lncyteBiosciencesDistribution8.V.,herebyfurtherconfirmthatWuzhouDruglnternationalTradingLimitedisalsoauthorizedtodistributesuchMacau-registeredProductintotheGreaterBayArea(GBA)ofthePeople'sRepublicofChina(excludingHongKongandMacao)throughitsdesignateddistributorChinaResourcesGuangdongPharmaceuticalCo.,Ltd.whichdistributorisdulyauthorizedundertheapplicablelaws,regulationsandpoliciestodistributeproductsuchastheProductintheGreaterBayAreaofthePeople'sRepublicofChina(excludingHongKongandMacao).4a\-"llncyteBiosciencesDistributionB.V.Etnt-D6fti^T$llt4+nBpmHnHPVLAA.iFlt)rlfHeTi4ltHif,frlFffi,iLh+Hffi.fRffiEHHti*t#.I*ffirtEwffijEfr#fx'a++R+rutrtfgX(Zr.E'+fr6yAfni4lDh+HizFffi.SOLVElncgteBiosciencesDistributionB.VPaasheuvetweg1105BPAmsterdam25ONNethertandwww.incute.comEIncyte此致Nncyte.NAMElncgteBiosciencesDistributionB.VSOLVEPaasheuvelweg251105BPAmsterdam0N.Nethertandwww.incgte.comThisauthorizationshallbeeffectiveonAugust15,2024untilfurthernoticeYoursfaithfully,BiosciencesDistributionB.V(MichaelMorrisseyONExecutiveVicePresident,&HeadofGlobalTechnicalOperationsPOSDATE29.08.2024授权书翻译对照参考：致启者：授权书2024年12月17日尊敬的先生/女士我们，ALK-AbelloA/S，特此授权远大医药集团有限公司在适用政策下，在中华人民共和国的大湾区（GBA），提供香港注册的Jext®（预充笔肾上腺素注射液，香港注册证编号：HK-64270）通过国药控股广州有限公司根据适用的政策在中华人民共和国大湾区区域销售等事宜。产品1Jext®300mcg预充笔肾上腺素注射液香港注册证编号：HK-64270此致，敬礼遠大醫藥集團有限公司NovartisPharmaceuticals(HK)Limited7/F.CitiTower.OneBayEast83HoiBunRoadKwunTong,Kowloon.HongKongTelephone+85228825222Fax+8522577027427tDecember.2024ChinaResourcesGuangdongPharmaceuticalCo.Limited10/F&5/F，CentralAreaNo.298YanjiangzhongRD.YuexiuDistrict,Guangzhou,GuangdongAttention:Ms.HouCaixia，InternationalBusinessTeamDearCaixia，Re:GBAAgreement-updatedAnnex1ProductListtoLetterofAuthorizationWeencloseafurtherupdatedAnnex1ProductList(v38)asupdatedon27tDecember2024forourLetterofAuthorizationdated15thNovember2021foryourrecord.Kindlyacknowledgeuponreceipt.Forenquiry,pleasefeelfreetocontactourHeadofBusinessExcellence&Strategy,Mr.AdrianMakbyemailatadrian.mak@novartis.comSincerelyDigtalysgnedbyMakAarianMakAdrianDN.doBerialNumber-3116384.cnDae:2024.12.2711:24:59+0800AdrianMakHeadofBusinessExcellence&StrategyNovartisPharmaceuticals(HK)LimitedEnclNovartisPharmaceuticals(HK)LimitedSuite2303-08.23/F，1111KingsRoad,TaikooShingHongKongTelephone+85228825222Fax+85225770274Annex1ProductList（pursuanttotheletterofauthorizationdated15November2021fromNovartisPharmaceuticals(HK)LimitedtoZuelligPharmaLimitedforGBADistributiontoChinaResourcesGuangdongPharmaceuticalCo.Limited）ThelistofproductscanbeupdatedfromtimetotimeandtheupdatedlistshallbesignedandstampedbyNovartisPharmaceuticals（HK）Limited:#ProductDesignatedGBAMedicalInstitutionGDMPAsdateofapproval1.PIQRAY(alpelisib)TheUniversityofHongKong-Shenzhen-Hospital27October20212.TABRECTA(capmatinib)ModernHospitalGuangzhougFebruary20223.BEOVU（brolucizumab)C-MERZhuhai)DennisLamEyeHospital9February20224.LEQVIO（inclisiran）GuangzhouUnitedFamilyHospital21sApril20225.LEQVIO(inclisiran）ZhongShanChenxinghaiHospital（AffiliatedZhongshanHospitalofGuangdongMedicalUniversity)29April20226.AIMOVIG（erenumab)GuangzhouUnitedFamilyHospital26May20227.BEOVU（brolucizumab)TheUniversityofHongKong-Shenzhen-Hospital21stJune20228.LEQVIO(inclisiran）TheUniversityofHongKong-Shenzhen-Hospital30June20229.AIMOVIG（erenumab)ZhongShanChenxinghaiHospital（AffiliatedZhongshanHospitalofGuangdongMedicalUniversity）1stAugust202210.AIMOVIG（erenumab)TheUniversityofHongKong-Shenzhen-Hospital2ndSeptember202211.AIMOVIG(erenumab)GuangzhouUnitedFamilyHospital7November202212.LEQVIO（inclisiran）GuangzhouUnitedFamilyHospital20January202313.TABRECTA(capmatinib)ModerHospitalGuangzhou13rdFebruary202314.LEQVIO（inclisiran）NanfangHospitalofSouthernMedicalUniversity14April202315.BEOVU（brolucizumab)C-MER(Zhuhai)DennisLamEyeHospital14April202316.LEQVIO(inclisiran）GuangzhouFirstPeople'sHospital，NanshaHospital10May202317.LEQVIO（inclisiran）ShenzhenHyzenHospital23rMay202318.LEQVIO（inclisiran）FoshanFuxingChanchengHospital23rdMay202319.LEQVIO（inclisiran）GuangdongCliffordHospital26May2023Annex1GBAProductListZPHKCRGD（v38updatedon20241227)Page1NovartisPharmaceuticals(HK)LimitedSuite2303-08.23/F，1111KingsRoad,TaikooShingHongKongTelephone+85228825222Fax+85225770274#ProductDesignatedGBAMedicalInstitutionGDMPAsdateofapproval20.BEOVU(brolucizumab)TheUniversityofHongKong-Shenzhen-Hospital29tMay202321.Piqray(Alpelisib)ShenzhenQianhaiShekouFreeTradeZoneHospital7June202322.LEQVIO(inclisiran）ShenzhenQianhaiShekouFreeTradeZoneHospital7June202323.AIMOVIG（erenumab)ZhongShanChenxinghaiHospital（AffiliatedZhongshanHospitalofGuangdongMedicalUniversity)13June202324.AIMOVIGerenumab)TheUniversityofHongKong-Shenzhen-Hospital13hJune202325.LEQVIO（inclisiran）ZhongShanChenxinghaiHospital（AffiliatedZhongshanHospitalofGuangdongMedicalUniversity)13June202326.TABRECTA(capmatinib)ModernHospitalGuangzhou29May202327.LEQVIO(inclisiran）HengqinBranchofZhuhaiPeoplesHospital25June202328.BEOVU(brolucizumab)C-MERGuangzhou)DennisLamEyeHospital25June202329.BEOVU（brolucizumab)C-MERShenzhen）DennisLamEyeHospital25June202330Piqray(Alpelisib)TheUniversityofHongKongShenzhen-Hospital10July202331.LEQVIO（inclisiran）TheUniversityofHongKong-Shenzhen-Hospital18July202332.BEOVU(brolucizumab)C-MERZhuhai)DennisLamEyeHospital7December202333.BEOVU（brolucizumab）C-MER(Guangzhou）DennisLamEyeHospital13December202334.BEOVU(brolucizumab)GuangzhouFirstPeoplesHospitalNanshaHospital15December202335.BEOVU（brolucizumab)C-MERShenzhen)DennisLamEyeHospital3dJanuary202436.BEOVU（brolucizumab)GuangzhouUnitedFamilyHospital4January202437.BEOVU（brolucizumab)TheUniversityofHongKong-ShenzhenHospital4January202438.BEOVU(brolucizumab)GuangdongProvincialPeople'sHospital4January2024Annex1GBAProductListZPHKCRGD(v38updatedon20241227)Page2NovartisPharmaceuticals(HK)LimitedSuite2303-08.23/F.1111King'sRoad,TaikooShingHongKongTelephone+85228825222Fax+85225770274#ProductDesignatedGBAMedicalInstitutionGDMPAsdateofapproval39.BEOVU(brolucizumab)GuangdongCliffordHospital10January202440.TABRECTA（capmatinib)TheFirstAffiliatedHospitalofSunYat-senUniversity15January202441.TABRECTA（capmatinib)ZhongShanChenxinghaiHospital（AffiliatedZhongshanHospitalofGuangdongMedicalUniversity)15January202442.BEOVU(brolucizumab)GuangzhouFirstPeoplesHospitalNanshaHospital20March202443.BEOVU（brolucizumab)DongguanGuangmingOphthalmicHospital26tMarch202444.BEOVU(brolucizumab)DongguanSongshanLakeTungwahHospital02ndDecember202445.BEOVU（brolucizumab)GuangdongProvincialPeoplesHospital31stOctober2024MakDigitalysignedbyMakAdrianDNdc=com.donovartisou=peope.oU=PHserialNumber=3116384.Adriancn=MakAdrianDate2024.12.2711:23:04+0800AdrianMakHeadofBusinessExcellence&StrategyForandonbehalfofNovartisPharmaceuticals(HK)LimitedDate:27December2024Annex1GBAProductListZPHKCRGD（v38updatedon20241227）Page3
投标 / 标书制作要点（原创）
本临床急需进口港澳药品配送服务 磷酸芦可替尼乳膏 薄膜包衣片 尘螨变应原舌下片 氟替美维吸入粉雾剂 预充笔肾上腺素注射液涉及「招标公告」，投标方需重点关注：① 营业执照经营范围须含招标公告或对应服务类目；② 提供同类项目业绩证明；③ 报价方案与售后响应须明确；④ 紧盯投标截止与开标节点，建议提前完成标书制作与盖章。深圳市项目常要求本地化服务能力与快速响应，务必在投标文件中凸显。
标书制作联系冯经理：17551026086
